J&J presents new data for TAR-200 intravesical delivery system
US healthcare giant Johnson & Johnson (NYSE: JNJ) has shared new findings for TAR-200, an intravesical gemcitabine releasing system, for patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC).
TAR-200 is inserted directly into the bladder in a brief outpatient procedure, without the need for anesthesia or sedation.
Two data cuts from Cohort 2 and Cohort 4 of the Phase IIb SunRISe-1 study were featured in the Paradigm-Shifting, Practice-Changing Clinical Trials in Urology plenary session at the 2025 American Urological Association (AUA) Annual Meeting, with findings representing the highest overall complete response rate for a monotherapy treatment observed for patients with this type of bladder cancer, along with the longest duration of response for monotherapy treatment., the company noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze